Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India

Singh, Shivaram Prasad; Kar, Sanjib; Panigrahi, Manas; Misra, Bijay; Pattnaik, Kaumudee; Bhuyan, Pallavi; Meher, Chudamani; Agrawal, Omprakash; Rout, Niranjan; Swain, Manorama

doi:10.7869/tg.118

Cited by 43 publications

(28 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The outcome well-matched with the studies of Duseja A and Singh SP et al where in the highest prevalence is seen among patients with BMI > 25 10,19 . This study is consistent with Amarapurkar D et al, Alam S et al, Singh SP et al, Somalwar AM et al and Hu X et al 13,14,23,24,25 Effect on Subjective Parameters Anorexia: In this study assessing anorexia before and after the treatment at various assessment days, it was found that, 7(35%) patients had mild anorexia, 1(5%) patient had moderate anorexia, 12 (60%) patients had no anorexia at baseline in group-A while 9 (45%) patients had mild anorexia, 1 (5%) patient had moderate anorexia, and 10 (50%) patients had no anorexia at baseline in group-B. After administration of Dawaul-Kurkum in group A and administration of placebo in group-B, at 60 th day, it was observed that anorexia was not present in any patients in group-A, while no improvement was found in group-B.…”

Section: Resultssupporting

confidence: 91%

Evaluation of the Efficacy of Dawa-Ul-Kurkum in Su-E-Mizaj Kabid Barid (Non-Alcoholic Fatty Liver Disease): A Randomized Single Blind Placebo Controlled Study

Hafeez¹,

Siddiqui²,

Khan³

et al. 2018

J Biol Sci Opin

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is emerging as an important cause of chronic liver disease, characterized by significant lipid deposition in hepatocytes. The prevalence of NAFLD in India is around 35% with higher prevalence in urban areas. In view of high prevalence and absence of any approved therapies for NAFLD, this clinical trial was attempted to evaluate the efficacy and safety of Dawa-ul-Kurkum in Non-alcoholic fatty liver disease (Su-e-Mizaj Kabid Barid). A randomized single blind placebo controlled trial was conducted in 44 cases of non-alcoholic fatty liver disease, diagnosed by ultra-sonogram of abdomen. They were randomly assigned in to two equal groups, after obtaining voluntary informed consent, of them 40 had completed the protocol and the rest 4 were lost to follow-up. Test group was administered Dawa-ul-Kurkum 5 gm once daily for 60 days, while the control group received Suji Halwa in similar dose and for same duration. All the cases were followed up every 15 th day. The results were statistically analyzed at the completion of trail. The test formulation showed statistically significant reduction in subjective and objective parameters (p<0.05), both in intergroup and intra group comparison, while placebo controlled group showed statistically insignificant effect (p>0.05). This study exhibits that the test drug; Dawa-ul-Kurkum has potential to reduce the symptoms and grading of NAFLD. There was no any adverse effect observed in this study. Hence it can be concluded that the test drug Dawa-ul-Kurkum is effective and safe in the management of NAFLD.

show abstract

Section: Resultssupporting

confidence: 91%

Evaluation of the Efficacy of Dawa-Ul-Kurkum in Su-E-Mizaj Kabid Barid (Non-Alcoholic Fatty Liver Disease): A Randomized Single Blind Placebo Controlled Study

Hafeez¹,

Siddiqui²,

Khan³

et al. 2018

J Biol Sci Opin

View full text Add to dashboard Cite

show abstract

“…20 In another study from costal eastern India, one fourth of patients had evidence of NASH on liver biopsy on presentation. 21 In another Asian study involving 52 patients, biopsy proven NASH at presentation was found in 32.6% patients while 23% patients with baseline NAFL progressed to NASH. 22 In contrast, a recent study from the West with mean 6.6 years follow up, baseline NASH was found in 75% patients with disease progression from NAFL to NASH in 44% patients.…”

mentioning

confidence: 95%

The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

Sharma

Mitnala

Vishnubhotla

et al. 2015

Journal of Clinical and Experimental Hepatology

128

View full text Add to dashboard Cite

Nonalcoholic fatty liver (NAFL) is an emerging global epidemic which progresses to nonalcoholic steatohepatitis (NASH) and cirrhosis in a subset of subjects. Various reviews have focused on the etiology, epidemiology, pathogenesis and treatment of NAFLD. This review highlights specifically the triggers implicated in disease progression from NAFL to NASH. The integrating role of genes, dietary factors, innate immunity, cytokines and gut microbiome have been discussed. ( J CLIN EXP HEPATOL 2015;5:147-158)

show abstract

“…In this study, 29% had lean NAFLD and 72% were overweight or obese [13]. In another study from our region, a significant proportion of NAFLD patients [16%] had normal BMI (lean body weight, BMI<23 kg/m 2 ) [14]. However studies from the West consistently employ BMI<25kg/m 2 as cut off for lean NAFLD [15][16][17][18][19].…”

Section: Definition Of Lean Nash and Justificationmentioning

confidence: 74%

The Lean NASH Conundrum

Singh¹,

Kar²

2015

J Diabetes Metab

Self Cite

View full text Add to dashboard Cite

show abstract

Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India

Abstract: In India, incidentally detected NAFLD (IDNAFLD) patients are predominantly middle aged males, most of whom are not lean. Most of these patients seek consultation for functional bowel disease.

Cited by 43 publications

References 44 publications

Evaluation of the Efficacy of Dawa-Ul-Kurkum in Su-E-Mizaj Kabid Barid (Non-Alcoholic Fatty Liver Disease): A Randomized Single Blind Placebo Controlled Study

Evaluation of the Efficacy of Dawa-Ul-Kurkum in Su-E-Mizaj Kabid Barid (Non-Alcoholic Fatty Liver Disease): A Randomized Single Blind Placebo Controlled Study

The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

The Lean NASH Conundrum

Contact Info

Product

Resources

About